Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Collaborative Health Research Projects

École Polytechnique de Montréal

$100,500.00

Improving the reliability of cytology diagnosis with immunoplasmonic multiplex labeling

FY 2018-19

Summary
Most cancer diagnoses are first established using a biopsy, and as such, biopsies are critical*to the health care of Canadians. Different types of biopsies are performed to achieve a*diagnosis, but physicians do prefer fine-needle aspiration cytology, hereafter referred to as*cytology, because it is associated with fewer side effects for the patients. Accordingly, the*number of cytology performed annually is increasing for many organs such as lung and*pancreas. Cytology is evaluated by pathologists, who are using different tools to refine their*diagnoses. The objective of the most commonly used tool is to detect proteins in the cells*which are specific for cancer. The multiple preparation steps that have to be performed to*colour those proteins can destroy said proteins and therefore affect the reliability of the tool.*Our objective is therefore to bypass the preparation steps by using metallic nanoparticles to*identify the proteins without degrading them, thus improving the reliability of the diagnosis.*Furthermore, we propose to use specific laser-based technologies to detect the metallic*nanoparticles. This project may be considered pioneering as clinical validation on human*cytology samples will ensure highly beneficial accuracy of diagnosis and optimal selection of*treatment, consequently improving the health of Canadian patients. To achieve this innovative*research project, we put together an excellent multidisciplinary and complementary team of*internationally renowned scientists and industrial partners coming from the full spectrum of*knowledge involved in this project. This team has already acquired a strong expertise in*metallic nanoparticles use and detection for biological diagnostics and we are recognized by*our peers as protein detection experts. Our excellence is demonstrated by multiple patents*and declarations of inventions. Our industrial partner, Photon etc, completes our skills in*commercialization of metallic nanoparticles and their detection.
Program
Collaborative Health Research Projects
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
523671-2018
Name nom
Meunier, Michel
Department département
Génie physique
Organization id
64
Institution établissement
École Polytechnique de Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
100500
Program id
CHRPJ
Program name en
Collaborative Health Research Projects
Program name fr
Projets de recherche concertée sur la santé
Group en
Discovery grants programs
Group fr
Programmes de subventions à la découverte
Committee code
360
Committee name en
Collaborative Health Research Projects Selection Panel
Committee name fr
Comité de sélection de projets de recherche concertée sur la santé
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
9999
Research subject group en
Not available
Research subject group fr
Non disponible
Research subject en
Not available
Research subject fr
Non disponible
Partie
1
Nb partie
1
Application title
Improving the reliability of cytology diagnosis with immunoplasmonic multiplex labeling
Keyword
NSERC
Application summary
Most cancer diagnoses are first established using a biopsy, and as such, biopsies are critical*to the health care of Canadians. Different types of biopsies are performed to achieve a*diagnosis, but physicians do prefer fine-needle aspiration cytology, hereafter referred to as*cytology, because it is associated with fewer side effects for the patients. Accordingly, the*number of cytology performed annually is increasing for many organs such as lung and*pancreas. Cytology is evaluated by pathologists, who are using different tools to refine their*diagnoses. The objective of the most commonly used tool is to detect proteins in the cells*which are specific for cancer. The multiple preparation steps that have to be performed to*colour those proteins can destroy said proteins and therefore affect the reliability of the tool.*Our objective is therefore to bypass the preparation steps by using metallic nanoparticles to*identify the proteins without degrading them, thus improving the reliability of the diagnosis.*Furthermore, we propose to use specific laser-based technologies to detect the metallic*nanoparticles. This project may be considered pioneering as clinical validation on human*cytology samples will ensure highly beneficial accuracy of diagnosis and optimal selection of*treatment, consequently improving the health of Canadian patients. To achieve this innovative*research project, we put together an excellent multidisciplinary and complementary team of*internationally renowned scientists and industrial partners coming from the full spectrum of*knowledge involved in this project. This team has already acquired a strong expertise in*metallic nanoparticles use and detection for biological diagnostics and we are recognized by*our peers as protein detection experts. Our excellence is demonstrated by multiple patents*and declarations of inventions. Our industrial partner, Photon etc, completes our skills in*commercialization of metallic nanoparticles and their detection.